Sarah Kathryn Rouan, Director at Viking Therapeutics, Inc. (VKTX), sold 30,000 shares at $23.05 ($692K) on 2024-01-19, disclosed to the SEC on 2024-01-19.
Scheduled sale ($692k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VKTX | SELL | 2024-02-08 | $701K | — | Filing → |
| NAVB | BUY | 2019-05-21 | $5K | — | Filing → |